SavedAdd your journal

Journals / Eurasian Journal of Emergency Medicine / 2019 / Cilt: 18 - Sayı: 2

Bangladesh National Drug Policy 1982-2016 and Recommendations in Policy Aspects

Munzur E. MURSHID
Mainul HAQUE
Pages
104–109
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Readers will know the past andpresent of the National Drug Policy of Bangladesh and will be able to assume the future of this policy in Bangladesh.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Science is progressing a lot in recent years.
📊
Key Findings & Data:Fortunately, that happened in Bangladeshafter the 1982 Drug Policy.
💡
Conclusion & Impact:Readers will know the past andpresent of the National Drug Policy of Bangladesh and will be able to assume the future of this policy in Bangladesh.
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Science is progressing a lot in recent years. Remarkable advances have been achieved in the field of health care technology. However,unfortunately, medicines are still the only hope for treating diseases for thousands of people in developing countries around the world.An effective National Drug Policy might be a lifesaving step for many people in these countries. Fortunately, that happened in Bangladeshafter the 1982 Drug Policy. In the meantime, the country has further editions of that policy, which were National Drug Policy 2005 & 2016.In this article, this research will discuss the comparative impact scenario of these policies in Bangladesh. Readers will know the past andpresent of the National Drug Policy of Bangladesh and will be able to assume the future of this policy in Bangladesh.

🔖

Cite This Article

MURSHID, M. E., HAQUE, M. (2022). Bangladesh National Drug Policy 1982-2016 and Recommendations in Policy Aspects. Eurasian Journal of Emergency Medicine, Cilt: 18 - Sayı: 2, 104–109. https://ajindex.com/articles/508031

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. World Health Organization. How to Develop and Implement a National Drug Policy. Second Edition. 2001. Available at http://apps.who.int/medicinedocs/ en/d/Js2283e/4.1.3.html [Accessed December 2, 2018] 2. World Health Organization. The selection and use of essential medicines. Report of the WHO Expert Committee, 2002 (including the 12th Model list of EMs). World Health Organ Tech Rep Ser. 2003;914:1-126. 3. World Health Organization. Making Drug Policy a Development Priority A Strategy Paper & Six Country Stories. 1995. Available at: http://apps.who.int/ medicinedocs/en/m/abstract/Js19174en/ [Accessed November-16-2018] 4. Ahmadiani S, Nikfar S. Challenges of access to medicine and the responsibility of pharmaceutical companies: a legal perspective. Daru. 2016;24:13. 5. Hoebert JM, van Dijk L, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. National medicines policies - a review of the evolution and development processes. J Pharm Policy Pract. 2013;6:5. 6. Kanji N, Hardon A, Harnmeijer JW, Mamdani M, Walt G. Drugs Policy in Developing Countries. London: Zed Books; 1992.p.136. 7. Frisher M, Martino O, Crome I, Croft P. Trends in drug misuse recorded in primary care in the UK from 1998 to 2005. J Public Health (Oxf). 2009;31:69- 73. 8. Mao W, Vu H, Xie Z, Chen W, Tang S. Systematic review on irrational use of medicines in China and Vietnam. PLoS One 2015;10:e0117710. 9. Ofori-Asenso R, Agyeman AA. Irrational Use of Medicines-A Summary of Key Concepts. Pharmacy (Basel). 2016:4. 10. Zaidi S, Bigdeli M, Aleem N, Rashidian A. Access to Essential Medicines in Pakistan: Policy and Health Systems Research Concerns. PLoS One. 2013;8:e63515. 11. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373:240-9. 12. Kanavos P, Das P, Durairaj V, Laing R, Dele Olawale Abegunde DO. Options for financing and optimizing medicines in resource-poor countries. World Health Report (2010)
  2. Background Paper, No 34. Health System Financing. The Path of Universal Coverage. World Health Organization. 2010. Available at http:// www.who.int/healthsystems/topics/financing/healthreport/34Medicinesrev. pdf [Accessed December 2, 2018] 13. Chowdhury FR, Ahasan HA, Rahman MM. National Drug Policy of Bangladesh: Some Pitfalls in Implementation. J Coll Physicians Surg Pak. 2006;16:368-70. 14. Islam N. Purity Poisoned. 1st ed. Dhaka: Momin Offset Press, 2007. 15. Chowdhury